|
1
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Crosbie EJ, Kitson SJ, McAlpine JN,
Mukhopadhyay A, Powell ME and Singh N: Endometrial cancer. Lancet.
399:1412–1428. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tronconi F, Nero C, Giudice E, Salutari V,
Musacchio L, Ricci C, Carbone MV, Ghizzoni V, Perri MT, Camarda F,
et al: Advanced and recurrent endometrial cancer: State of the art
and future perspectives. Crit Rev Oncol Hematol. 180:172022.
View Article : Google Scholar
|
|
4
|
Makker V, Green AK, Wenham RM, Mutch D,
Davidson B and Miller DS: New therapies for advanced, recurrent,
and metastatic endometrial cancers. Gynecol Oncol Res Pract.
4:192017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nero C, Tronconi F, Giudice E, Scambia G
and Lorusso D: Management of stage III and IVa uterine cancer. Int
J Gynecol Cancer. 32:316–322. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
van den Heerik A, Horeweg N, de Boer SM,
Bosse T and Creutzberg CL: Adjuvant therapy for endometrial cancer
in the era of molecular classification: Radiotherapy,
chemoradiation and novel targets for therapy. Int J Gynecol Cancer.
31:594–604. 2021. View Article : Google Scholar :
|
|
7
|
LoRusso PM: Inhibition of the
PI3K/AKT/mTOR pathway in solid tumors. J Clin Oncol. 34:3803–3815.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Roncolato F, Lindemann K, Willson ML,
Martyn J and Mileshkin L: PI3K/AKT/mTOR inhibitors for advanced or
recurrent endometrial cancer. Cochrane Database Syst Rev.
10:CD0121602019.PubMed/NCBI
|
|
9
|
Bang YJ, Kang YK, Ng M, Chung HC, Wainberg
ZA, Gendreau S, Chan WY, Xu N, Maslyar D, Meng R, et al: A phase
II, randomised study of mFOLFOX6 with or without the Akt inhibitor
ipatasertib in patients with locally advanced or metastatic gastric
or gastroesophageal junction cancer. Eur J Cancer. 108:17–24. 2019.
View Article : Google Scholar
|
|
10
|
Chan JJ, Tan TJY and Dent RA: Novel
therapeutic avenues in triple-negative breast cancer: PI3K/AKT
inhibition, androgen receptor blockade, and beyond. Ther Adv Med
Oncol. 11:17588359198804292019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
de Bono JS, De Giorgi U, Rodrigues DN,
Massard C, Bracarda S, Font A, Arranz Arija JA, Shih KC, Radavoi
GD, Xu N, et al: Randomized phase II study evaluating akt blockade
with ipatasertib, in combination with abiraterone, in patients with
metastatic prostate cancer with and without PTEN loss. Clin Cancer
Res. 25:928–936. 2019. View Article : Google Scholar
|
|
12
|
Isakoff SJ, Tabernero J, Molife LR, Soria
JC, Cervantes A, Vogelzang NJ, Patel MR, Hussain M, Baron A,
Argilés G, et al: Antitumor activity of ipatasertib combined with
chemotherapy: Results from a phase Ib study in solid tumors. Ann
Oncol. 31:626–633. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim SB, Dent R, Im SA, Espié M, Blau S,
Tan AR, Isakoff SJ, Oliveira M, Saura C, Wongchenko MJ, et al:
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as
first-line therapy for metastatic triple-negative breast cancer
(LOTUS): A multicentre, randomised, double-blind,
placebo-controlled, phase 2 trial. Lancet Oncol. 18:1360–1372.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Morgillo F, Della Corte CM, Diana A, Mauro
CD, Ciaramella V, Barra G, Belli V, Franzese E, Bianco R, Maiello
E, et al: Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade
with taselisib or ipatasertib enhances the efficacy of
anti-microtubule drugs in human breast cancer cells. Oncotarget.
8:76479–76491. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Oliveira M, Saura C, Nuciforo P, Calvo I,
Andersen J, Passos-Coelho JL, Gil Gil M, Bermejo B, Patt DA,
Ciruelos E, et al: FAIRLANE, a double-blind placebo-controlled
randomized phase II trial of neoadjuvant ipatasertib plus
paclitaxel for early triple-negative breast cancer. Ann Oncol.
30:1289–1297. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Saura C, Roda D, Roselló S, Oliveira M,
Macarulla T, Pérez-Fidalgo JA, Morales-Barrera R, Sanchis-García
JM, Musib L, Budha N, et al: A First-in-Human phase I study of the
ATP-competitive AKT inhibitor ipatasertib demonstrates robust and
safe targeting of AKT in patients with Solid tumors. Cancer Discov.
7:102–113. 2017. View Article : Google Scholar :
|
|
17
|
Shapiro GI, LoRusso P, Cho DC, Musib L,
Yan Y, Wongchenko M, Chang I, Patel P, Chan IT, Sanabria-Bohorquez
S, et al: A phase Ib open-label dose escalation study of the
safety, pharmacokinetics, and pharmacodynamics of cobimetinib
(GDC-0973) and ipatasertib (GDC-0068) in patients with locally
advanced or metastatic solid tumors. Invest New Drugs. 39:163–174.
2021. View Article : Google Scholar
|
|
18
|
Lin J, Sampath D, Nannini MA, Lee BB,
Degtyarev M, Oeh J, Savage H, Guan Z, Hong R, Kassees R, et al:
Targeting activated Akt with GDC-0068, a novel selective Akt
inhibitor that is efficacious in multiple tumor models. Clin Cancer
Res. 19:1760–1772. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Buckingham L, Hao T, O'Donnell J, Zhao Z,
Zhang X, Fan Y, Sun W, Zhang Y, Suo H, Secord AA, et al:
Ipatasertib, an oral AKT inhibitor, inhibits cell proliferation and
migration, and induces apoptosis in serous endometrial cancer. Am J
Cancer Res. 12:2850–2862. 2022.PubMed/NCBI
|
|
20
|
Dent R, Oliveira M, Isakoff SJ, Im SA,
Espié M, Blau S, Tan AR, Saura C, Wongchenko MJ, Xu N, et al: Final
results of the double-blind placebo-controlled randomized phase 2
LOTUS trial of first-line ipatasertib plus paclitaxel for
inoperable locally advanced/metastatic triple-negative breast
cancer. Breast Cancer Res Treat. 189:377–386. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sweeney C, Bracarda S, Sternberg CN, Chi
KN, Olmos D, Sandhu S, Massard C, Matsubara N, Alekseev B, Parnis
F, et al: Ipatasertib plus abiraterone and prednisolone in
metastatic castration-resistant prostate cancer (IPATential150): A
multi-centre, randomised, double-blind, phase 3 trial. Lancet.
398:131–142. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guo H, Kong W, Zhang L, Han J, Clark LH,
Yin Y, Fang Z, Sun W, Wang J, Gilliam TP, et al: Reversal of
obesity-driven aggressiveness of endometrial cancer by metformin.
Am J Cancer Res. 9:2170–2193. 2019.PubMed/NCBI
|
|
23
|
Staley A, Tucker K, Yin Y, Zhang X, Fan Y,
Zhang Y, Fang Z, Sun W, Suo H, Zhao X, et al: Highly potent
dopamine receptor D2 antagonist ONC206 demonstrates
anti-tumorigenic activity in endometrial cancer. Am J Cancer Res.
11:5374–5387. 2021.PubMed/NCBI
|
|
24
|
Pierce SR, Fang Z, Yin Y, West L, Asher M,
Hao T, Zhang X, Tucker K, Staley A, Fan Y, et al: Targeting
dopamine receptor D2 as a novel therapeutic strategy in endometrial
cancer. J Exp Clin Cancer Res. 40:612021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kaminskyy VO and Zhivotovsky B: Free
radicals in cross talk between autophagy and apoptosis. Antioxid
Redox Signal. 21:86–102. 2014. View Article : Google Scholar
|
|
26
|
Kodack DP, Farago AF, Dastur A, Held MA,
Dardaei L, Friboulet L, von Flotow F, Damon LJ, Lee D, Parks M, et
al: Primary patient-derived cancer cells and their potential for
personalized cancer patient care. Cell Rep. 21:3298–3309. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cheung LW, Hennessy BT, Li J, Yu S, Myers
AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, et al:
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer
elucidates a novel mechanism for regulation of PTEN protein
stability. Cancer Discov. 1:170–185. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mazloumi Gavgani F, Smith Arnesen V,
Jacobsen RG, Krakstad C, Hoivik EA and Lewis AE: Class I
Phosphoinositide 3-Kinase PIK3CA/p110α and PIK3CB/p110β Isoforms in
Endometrial Cancer. Int J Mol Sci. 19:39312018. View Article : Google Scholar
|
|
29
|
Lin K, Lin J, Wu WI, Ballard J, Lee BB,
Gloor SL, Vigers GP, Morales TH, Friedman LS, Skelton N and
Brandhuber BJ: An ATP-site on-off switch that restricts phosphatase
accessibility of Akt. Sci Signal. 5:ra372012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pavlidou A and Vlahos NF: Molecular
alterations of PI3K/Akt/mTOR pathway: A therapeutic target in
endometrial cancer. Scientific World Journal. 2014:7097362014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Blake JF, Xu R, Bencsik JR, Xiao D, Kallan
NC, Schlachter S, Mitchell IS, Spencer KL, Banka AL, Wallace EM, et
al: Discovery and preclinical pharmacology of a selective
ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human
tumors. J Med Chem. 55:8110–8127. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yu L, Liu Z, Qiu L, Hao L and Guo J:
Ipatasertib sensitizes colon cancer cells to TRAIL-induced
apoptosis through ROS-mediated caspase activation. Biochem Biophys
Res Commun. 519:812–818. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cocco S, Leone A, Roca MS, Lombardi R,
Piezzo M, Caputo R, Ciardiello C, Costantini S, Bruzzese F, Sisalli
MJ, et al: Inhibition of autophagy by chloroquine prevents
resistance to PI3K/AKT inhibitors and potentiates their antitumor
effect in combination with paclitaxel in triple negative breast
cancer models. J Transl Med. 20:2902022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sun L, Huang Y, Liu Y, Zhao Y, He X, Zhang
L, Wang F and Zhang Y: Ipatasertib, a novel Akt inhibitor, induces
transcription factor FoxO3a and NF-κB directly regulates
PUMA-dependent apoptosis. Cell Death Dis. 9:9112018. View Article : Google Scholar
|
|
35
|
Savill KMZ, Lee BB, Oeh J, Lin J, Lin E,
Chung WJ, Young A, Chen W, Miś M, Mesh K, et al: Distinct
resistance mechanisms arise to allosteric vs. ATP-competitive AKT
inhibitors. Nat Commun. 13:20572022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Koundouros N and Poulogiannis G:
Phosphoinositide 3-Kinase/Akt signaling and redox metabolism in
cancer. Front Oncol. 8:1602018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Aggarwal V, Tuli HS, Varol A, Thakral F,
Yerer MB, Sak K, Varol M, Jain A, Khan MA and Sethi G: Role of
reactive oxygen species in cancer progression: Molecular mechanisms
and recent advancements. Biomolecules. 9:7352019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Asaduzzaman Khan M, Tania M, Zhang DZ and
Chen HC: Antioxidant enzymes and cancer. Chin J Cancer Res.
22:87–92. 2010. View Article : Google Scholar
|
|
39
|
Girouard J, Lafleur MJ, Parent S, Leblanc
V and Asselin E: Involvement of Akt isoforms in chemoresistance of
endometrial carcinoma cells. Gynecol Oncol. 128:335–343. 2013.
View Article : Google Scholar
|
|
40
|
Gagnon V, Van Themsche C, Turner S,
Leblanc V and Asselin E: Akt and XIAP regulate the sensitivity of
human uterine cancer cells to cisplatin, doxorubicin and taxol.
Apoptosis. 13:259–271. 2008. View Article : Google Scholar
|
|
41
|
Fabi F, Adam P, Parent S, Tardif L, Cadrin
M and Asselin E: Pharmacologic inhibition of Akt in combination
with chemotherapeutic agents effectively induces apoptosis in
ovarian and endometrial cancer cell lines. Mol Oncol. 15:2106–2119.
2021. View Article : Google Scholar :
|
|
42
|
Turner N, Dent RA, O'Shaughnessy J, Kim
SB, Isakoff SJ, Barrios C, Saji S, Bondarenko I, Nowecki Z, Lian Q,
et al: Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered
hormone receptor-positive HER2-negative advanced breast cancer:
Primary results from cohort B of the IPATunity130 randomized phase
3 trial. Breast Cancer Res Treat. 191:565–576. 2022. View Article : Google Scholar :
|
|
43
|
Veerabhadrappa B, Subramanian S, S J S and
Dyavaiah M: Evaluating the genetic basiss of anti-cancer property
of Taxol in Saccharomyces cerevisiae model. FEMS Microbiol Lett.
368:fnab0772021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhao X, Kong W, Tucker K, Staley A, Fan Y,
Sun W, Yin Y, Huang Y, Fang Z, Wang J, et al: SPR064, a pro-drug of
paclitaxel, has anti-tumorigenic effects in endometrial cancer cell
lines and mouse models. Am J Transl Res. 12:4264–4276.
2020.PubMed/NCBI
|
|
45
|
Shariati M and Meric-Bernstam F: Targeting
AKT for cancer therapy. Expert Opin Investig Drugs. 28:977–988.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shi Z, Wulfkuhle J, Nowicka M, Gallagher
RI, Saura C, Nuciforo PG, Calvo I, Andersen J, Passos-Coelho JL,
Gil-Gil MJ, et al: Functional mapping of AKT signaling and
biomarkers of response from the FAIRLANE trial of neoadjuvant
ipatasertib plus paclitaxel for triple-negative breast cancer. Clin
Cancer Res. 28:993–1003. 2022. View Article : Google Scholar
|
|
47
|
Kasius JC, Pijnenborg JMA, Lindemann K,
Forsse D, van Zwol J, Kristensen GB, Krakstad C, Werner HMJ and
Amant F: Risk stratification of endometrial cancer patients: FIGO
stage, biomarkers and molecular classification. Cancers.
13:58482021. View Article : Google Scholar : PubMed/NCBI
|
